However, the rationale for the use of targeted agents such as PARP1 inhibitors (PARP1i) in BRCA2‐deficient cancers is contingent upon bi‐allelic BRCA2 inactivation in the tumour cells (Bryant et al., 2005; Farmer et al., 2005). This evidence concerns the gene BRCA2 and cancer.